Invest-NL invests € 20 million in Vitestro for international rollout of autonomous blood sampling

Vitestro is developing a blood sampling robot that automates diagnostic blood collection. The system combines robotics, artificial intelligence, and advanced ultrasound to detect veins, accurately position a needle, and collect blood samples. This technology can help healthcare providers work more efficiently, improve the quality of blood draws, and reduce staff shortages.

Invest-NL as a Catalyst for the Consortium

The investment from Invest-NL amounts to € 20 million and was made possible in part by an InvestEU guarantee. Invest-NL was the foundation of this funding round and contributed to bringing together a consortium of renowned international partners. 

Among the new investors are leading organizations such as Mayo Clinic – one of the most prominent hospital systems in the United States, and Labcorp – one of the largest clinical laboratory networks in the world. Also participating are Sutter Health and financial entities like InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht. In addition to Invest-NL, existing investors EIC Fund, NYBC Ventures, and Sonder Capital are also taking part in this round.

Accelerating International Deployment

With the new financing, Vitestro is working on further developing its Aletta® Autonomous Robotic Phlebotomy Device™ and preparing for a broader market introduction. The commercial rollout begins in the Netherlands at hospitals participating in clinical studies with the system. This is followed by expansion into other European markets, with Denmark as the first step, and commercial deployment in the United States. 

Through this investment, we aim to make autonomous blood collection available worldwide and contribute to a more efficient and future-proof healthcare system.